After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug ...

Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has plenty ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...

Ferring Pharmaceuticals is halting work on two trials of a phase 1 infertility candidate that together had enrolled 416 ...

Newly uncloaked Stipple Bio is connecting the dots toward multiple early-stage clinical studies for its lead precision ...

Epia Neuro is the latest medtech startup looking to tap the potential of brain-computer interface (BCI) technology, launching ...

People in the U.S. are increasingly missing cancer screenings and worry as much about a diagnosis as they do about the cost ...

Premier Radiology Services, which has been on an acquisition tear in the last year, snapped up fellow teleradiology ...

Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the ...